Thursday, July 17, 2008

Amgen Announces Webcast of 2008 Second Quarter Financial Results

THOUSAND OAKS, Calif., Jul 17, 2008 – Amgen (NASDAQ:AMGN) today announced that it plans to report its second quarter financial results on Monday, July 28, 2008 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team.

Read the rest of this entry

Posted in Press Releases

Tuesday, July 15, 2008

Study Showed Half of Patients Treated with Enbrel(R) (etanercept) Plus Methotrexate Can Achieve DAS Clinical Remission and 80 Percent Had No Progression of Joint Damage in Active Early Rheumatoid Arthritis

Data Demonstrated Benefits of Early Treatment in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA)

COLLEGEVILLE, Pa. & THOUSAND OAKS, Calif. – July 15, 2008 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Amgen (NASDAQ:AMGN) today announced the publication of data from the COMET (COmbination of Methotrexate and ETanercept in Active Early Rheumatoid Arthritis) trial demonstrating that half of patients treated with the combination of ENBREL and methotrexate achieved Disease Activity Score (DAS) clinical remission and nearly all had no progression of joint damage. These findings were published online on July 15 by The Lancet, a leading global medical journal.

Read the rest of this entry

Posted in Press Releases

Monday, July 14, 2008

Business Wire Issues Retraction of Nplate Press Release

Business Wire requests that BW5644, Amgen Inc. press release entited "FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP" be killed. The release was issued prematurely by Business Wire.

Read the rest of this entry

Posted in Press Releases

Monday, July 14, 2008

Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy

 Data From First Pivotal Study in Men Met Primary Endpoint of Increases in Bone Mineral Density and Secondary Endpoint of New Vertebral Fracture Reduction

THOUSAND OAKS, Calif. – Jul 14, 2008 – Amgen (NASDAQ:AMGN) today announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer.

Read the rest of this entry

Posted in Press Releases

Thursday, July 10, 2008

Amgen Commits to PhRMA's Enhanced Code on Interactions with Healthcare Professionals as Part of the Company's 'Clearly Amgen' Initiative

 THOUSAND OAKS, Calif. – July 10, 2008 – Amgen (NASDAQ: AMGN) today announced its intent to comply with the Pharmaceutical Research and Manufacturers of America’s (PhRMA) revised "Code on Interactions with U.S. Healthcare Professionals." The company’s announcement of its voluntary support for the Code is the latest element of Clearly Amgen, the company’s ongoing initiative to provide clear communications about and easy access to Amgen’s policies and practices on ethical research, clinical data disclosure, responsible marketing and other topics of interest to Amgen stakeholders.

Read the rest of this entry

Posted in Philanthropy, Press Releases